Glaxo Pharma Financial Statements

Glaxo Pharma (GLAXO) reported revenue of ₹38.22B in FY2026 with net income of ₹10.36B. Total assets stood at ₹43.24B and free cash flow was ₹8.48B.

Glaxo Pharma Income Statement

Hover the chart icon for year-over-year change.

FY 2025 – FY 2026

Item	Chart	2025	2026
Revenue		38.95B	38.22B
Cost of Rev. Cost of Revenue		-13.91B	-13.51B
Gross Profit		25.04B	24.71B
SGA Sales, General & Admin		-11.81B	-6.07B
Op. Income Operating Income		12.57B	12.43B
PBT Profit Before Tax		12.60B	14.06B
Net Income		9.28B	10.36B
Dil. Shares Diluted Shares		169.39M	169.41M
Diluted EPS		54.76	61.15

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Glaxo Pharma's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Glaxo Pharma Balance Sheet

Hover the chart icon for year-over-year change.

FY 2025 – FY 2026

Item	Chart	2025	2026
Curr. assets Total current assets		34.10B	36.06B
Non-curr. assets Total non-current assets		6.98B	7.18B
Total assets		41.08B	43.24B
Curr. liabilities Total current liabilities		19.05B	17.79B
Non-curr. liab. Total non-current liabilities		2.52B	2.77B
Total liabilities		21.57B	20.56B
Total equity		19.51B	22.67B
Total liab. & eq. Total liabilities & equity		41.08B	43.24B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Glaxo Pharma's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Glaxo Pharma Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2025 – FY 2026

Item	Chart	2025	2026
Net Income		12.55B	13.85B
Operating CF Cash flow Operating Activities		12.90B	9.03B
Capex Investments in PPE		-230.22M	-552.79M
Investing CF Cash flow Investing Activities		-458.01M	3.97B
Dividend Paid		-7.49B	-7.14B
Financing CF Cash flow Financing Activities		-7.69B	-7.37B
Cash (start) Cash at beginning of period		641.71M	5.39B
Cash (end) Cash at end of period		5.39B	11.02B
FCF Free Cash Flow		12.67B	8.48B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Glaxo Pharma's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2026